Vebreltinib for advanced clear cell sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests the drug vebreltinib for people with advanced or spreading clear cell sarcoma. The goal is to see if it can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 12 years old
- Have a type of cancer called clear cell sarcoma that cannot be removed by surgery or has spread
- Be in generally good health, with normal heart, liver, kidney, and blood function
- Agree to use reliable birth control during treatment and for 12 months after
- Cannot have had specific prior treatments like cabozantinib or other MET inhibitors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called tebentafusp can help people with advanced clear cell sarcoma that cannot be removed by surgery or has spread. It is for people with a specific immune marker (HLA-A*02:01) whose disease has gotten worse.
This trial tests a targeted drug called vebreltinib given before surgery to people with a specific type of non-small cell lung cancer that has a MET gene change. The goal is to see if it can shrink the tumor enough to make surgery more successful.
This trial tests a new targeted drug, vebreltinib, combined with standard chemotherapy as the first treatment for advanced non-small cell lung cancer that has a specific marker called MET overexpression. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
This study tests a combination of two drugs (anlotinib and bempegaldesleukin) plus standard chemotherapy and radiation for people with advanced soft tissue sarcoma that has spread or can't be removed. The goal is to see if this combination helps shrink tumors and control the cancer.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial tests a combination of three drugs—liposomal irinotecan, temozolomide, and bevacizumab—for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery and has not responded to previous treatments. The goal is to see if this combination can help control the cancer.
Hear when a new Clear Cell Sarcoma (CCS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.